VistaGen Therapeutics, Inc.
VTGN
$2.22
-$0.12-5.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -43.07% | -34.17% | -52.54% | 12.17% | 128.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.07% | -34.17% | -52.54% | 12.17% | 128.84% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -43.07% | -34.17% | -52.54% | 12.17% | 128.84% |
| SG&A Expenses | 7.74% | 30.81% | 53.36% | 33.85% | 21.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.10% | 104.17% | 70.24% | -6.92% | -16.60% |
| Operating Income | -91.78% | -109.84% | -73.35% | 7.19% | 19.28% |
| Income Before Tax | -121.87% | -96.63% | -55.55% | 22.14% | 34.95% |
| Income Tax Expenses | -- | -- | -- | 200.00% | -- |
| Earnings from Continuing Operations | -121.87% | -96.74% | -55.48% | 22.13% | 34.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.87% | -96.74% | -55.48% | 22.13% | 34.95% |
| EBIT | -91.78% | -109.84% | -73.35% | 7.19% | 19.28% |
| EBITDA | -92.04% | -110.25% | -73.66% | 7.20% | 19.34% |
| EPS Basic | -112.26% | 35.50% | 62.72% | 81.73% | 84.74% |
| Normalized Basic EPS | -112.37% | 35.54% | 62.71% | 81.74% | 84.74% |
| EPS Diluted | -112.26% | 35.50% | 62.72% | 81.62% | 84.74% |
| Normalized Diluted EPS | -112.37% | 35.54% | 62.71% | 81.74% | 84.74% |
| Average Basic Shares Outstanding | 4.50% | 205.03% | 317.11% | 326.26% | 326.25% |
| Average Diluted Shares Outstanding | 4.50% | 205.03% | 317.11% | 326.26% | 326.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |